Literature DB >> 9192060

The natural history of ulcerative colitis.

W Selby1.   

Abstract

The majority of patients with ulcerative colitis (UC) will run a typical chronic, relapsing course. The proportion with chronic, continuous symptoms diminishes with time. The greatest impact of the disease is in the first few years after diagnosis, especially in patients with extensive or severe colitis. After this time, the likelihood of requiring surgery declines rapidly, and survival is no different from that of the general population. The long-term course can be best predicted by the course in the preceding period. Most patients are able to lead an essentially normal lifestyle, at work and at home, with either medical or surgical treatment. Awareness of how the patient feels the disease affects his or her life is important. Educating the patient about their illness will also help in management.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192060     DOI: 10.1016/s0950-3528(97)90053-1

Source DB:  PubMed          Journal:  Baillieres Clin Gastroenterol        ISSN: 0950-3528


  7 in total

Review 1.  Crucial steps in the natural history of inflammatory bowel disease.

Authors:  Giovanni Latella; Claudio Papi
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 2.  Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.

Authors:  Abbi R Saniabadi; Tomotaka Tanaka; Toshihide Ohmori; Koji Sawada; Takayuki Yamamoto; Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 3.  Value of colonoscopy for prediction of prognosis in patients with ulcerative colitis.

Authors:  Takafumi Ando; Yuji Nishio; Osamu Watanabe; Hironao Takahashi; Osamu Maeda; Kazuhiro Ishiguro; Daisuke Ishikawa; Naoki Ohmiya; Yasumasa Niwa; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

4.  Magnifying chromoscopy, a novel and useful technique for colonoscopy in ulcerative colitis.

Authors:  Takafumi Ando; Hironao Takahashi; Osamu Watanabe; Osamu Maeda; Kazuhiro Ishiguro; Daisuke Ishikawa; Motofusa Hasegawa; Naoki Ohmiya; Yasumasa Niwa; Hidemi Goto
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

5.  Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy.

Authors:  Na Li; Jingwei Mao; Haiying Tang; Lei Zhu; Xiaoyan Tan; Jian Bi; Hao Wu; Xiuli Chen; Yingde Wang
Journal:  J Clin Apher       Date:  2020-05-07       Impact factor: 2.821

6.  Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study.

Authors:  Satoshi Motoya; Hiroki Tanaka; Tomoyoshi Shibuya; Taro Osada; Takayuki Yamamoto; Hitoshi Hongo; Chiemi Mizuno; Daisuke Saito; Nobuo Aoyama; Toshihisa Kobayashi; Hiroaki Ito; Satoshi Tanida; Masanori Nojima; Seiichiro Kokuma; Eiji Hosoi
Journal:  BMC Gastroenterol       Date:  2019-11-21       Impact factor: 3.067

7.  Predicting a rapid response to adalimumab treatment and favorable short-term outcomes through the high platelet count in patients with ulcerative colitis: A multicenter retrospective cohort study.

Authors:  Ryosuke Sakemi; Maki Miyakawa; Hiroki Tanaka; Masanao Nasuno; Satoshi Motoya; Tokuma Tanuma; Manabu Ishii; Hideyuki Yanagisawa; Masaki Yamashita; Nariaki Toita; Ryo Suzuki; Toshihisa Kobayashi; Masanori Nojima; Suketo So
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.